Centanafadine (Simtriyo) for Executive Dysfunction in ADHD

November 12, 2026by Chris Aiken, MD0
A newly approved medication for ADHD may help executive functioning, but the result rests on secondary findings

STUDY: Wilens TE et al, J Child Adolesc Psychopharmacol 2026

STUDY TYPE: Post hoc analysis of two randomized controlled trials

FUNDING: Otsuka Pharmaceutical (manufacturer)

Background

Children with severe executive dysfunction tend to respond less to standard ADHD medications. Centanafadine (Simtriyo) is a newly approved ADHD medication blocks reuptake of norepinephrine, dopamine, and serotonin, and this analysis looked at that outcome in the FDA-registry trials.

The Study
  • Two 6-week placebo-controlled trials in children (6–12) and adolescents (13–17), pooled together.
  • Focused on 435 of 586 patients (74%) who had very elevated executive dysfunction on a parent-rated ADHD scale (Conners 3–Parent Short).
Results

In the high-dysfunction group, centanafadine improved core symptoms on the ADHD scale (ADHD-RS-5) from week 1 (effect sizes 0.35–0.51). By week 6, they resembled patients with milder executive problems.

Here are the effect sizes on Conners subscales (which are notably lower than typical effects with stimulants):

  • Inattention: 0.33–0.56
  • Executive function: 0.34–0.53
  • Learning problems: 0.36–0.52
  • Defiance/aggression: 0.19–0.36

At week 6, 42% on centanafadine had dropped below the clinically elevated range for executive function, versus 26% on placebo.

Side Effects

Decreased appetite (13% vs 3%), nausea (7% vs 1%), and rash (5% vs 0%) were more common. Side effects led 7.6% to stop centanafadine versus 0.9% on placebo (number needed to harm, NNH about 15).

Limitations
  • Post hoc, with no correction for multiple comparisons.
  • Otsuka funded and helped write it; four authors are employees.
  • Short term, parent ratings only, no comparison to traditional stimulants.
  • Regression to the mean may inflate gains in sicker patients.
Practice Implications
  1. Recently, the DEA placed cetanafadine as a schedule III control, less controlled than stimulants (which are schedule III)
  2. While these results are encouraging, other treatments for ADHD improve executive functioning. Stimulants remain first line, with less data and possibly lower effect for centanafadine.

—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report

What’s Your Take? Share in Comments

Leave a Reply

Your email address will not be published. Required fields are marked *